Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

42.12 +0.34 (+0.81%)
Streaming Delayed Price Updated: 10:56 AM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Value Investment Opportunity ↗
Discover EXELIXIS (EXEL), a value stock with strong profitability, zero debt, and solid growth, trading at an attractive discount to its industry peers. 
Via Chartmill
News headline image
Exelixis Inc (NASDAQ:EXEL) Emerges as a Top Affordable Growth Stock ↗
Exelixis (EXEL) is a GARP stock with strong earnings growth, a reasonable valuation, and a debt-free balance sheet. 
Via Chartmill
News headline image
S&P 500 Surges as Congress Nears End to Protracted Government Shutdown
Washington D.C. – November 10, 2025 – Global financial markets are breathing a collective sigh of relief today as the S&P 500 index experiences a significant uplift, signaling investor optimism over... 
Via MarketMinute
Topics Economy Regulatory Compliance Stocks
News headline image
Global Markets Rally on Hopes for US Government Shutdown Resolution
Global financial markets are breathing a collective sigh of relief, with stock futures surging as investors cling to cautious optimism for an imminent end to the protracted United States government... 
Via MarketMinute
Topics Bonds Economy Government
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Preview: Exelixis's Earnings ↗
 
Via Benzinga
News headline image
What's Driving the Market Sentiment Around Exelixis Inc? ↗
 
Via Benzinga
News headline image
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer ↗
Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer. 
Via Benzinga
News headline image
17 Analysts Have This To Say About Exelixis ↗
 
Via Benzinga
News headline image
Peering Into Exelixis's Recent Short Interest ↗
 
Via Benzinga
News headline image
EXELIXIS INC (NASDAQ:EXEL) Represents an Affordable Growth Opportunity ↗
Discover EXELIXIS (EXEL), an affordable growth stock with strong profitability, sound finances, and a compelling valuation in the biotech sector. 
Via Chartmill
News headline image
This Nextracker Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks You'll Regret Missing In October ↗
 
Via Benzinga
News headline image
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients. 
Via Benzinga
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Is the Market Bullish or Bearish on Exelixis? ↗
 
Via Benzinga
News headline image
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
The Ultimate Biotech Stock to Buy With $50 Right Now ↗
This innovative drugmaker still has plenty of upside potential. 
Via The Motley Fool
News headline image
EXELIXIS INC (NASDAQ:EXEL) Identified as a Quality Value Stock by Fundamental Screening ↗
Exelixis (EXEL) presents a strong value investment case with low P/E ratios, zero debt, robust profitability, and solid growth in the biotech sector. 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) Stands Out as an Affordable Growth Stock ↗
Discover EXELIXIS INC (EXEL), an affordable growth stock with strong financials, impressive earnings, and a discounted valuation in the biotech sector. 
Via Chartmill
News headline image
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years ↗
Both should have significant catalysts by the end of the decade. 
Via The Motley Fool
News headline image
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Undervalued Stock with Strong Fundamentals ↗
EXELIXIS (EXEL) emerges as a top value stock with strong fundamentals: undervalued, zero debt, high profitability, and solid growth in the biotech sector. 
Via Chartmill
News headline image
Exelixis Inc (NASDAQ:EXEL) Embodies the Affordable Growth Investment Strategy ↗
Exelixis (EXEL) offers affordable growth with strong oncology revenue, high profitability, a robust balance sheet, and attractive valuation metrics. 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity ↗
Exelixis (EXEL) is a strong value investing candidate, trading below intrinsic value with a solid financial profile, high profitability, and strong growth prospects. 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Growth at a Reasonable Price (GARP) Stock ↗
EXELIXIS INC (EXEL) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity. 
Via Chartmill
News headline image
Exelixis Inc (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Setup ↗
Exelixis (EXEL) is a strong growth stock with solid fundamentals—17.5% revenue growth, high profitability, and no debt—plus a bullish technical setup, signaling a potential breakout opportunity. 
Via Chartmill
News headline image
The Analyst Verdict: Exelixis In The Eyes Of 19 Experts ↗
 
Via Benzinga
News headline image
Exelixis EXEL Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio? ↗
Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.